Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Type of study
Language
Publication year range
1.
Int J Pharm ; 624: 122027, 2022 Aug 25.
Article in English | MEDLINE | ID: mdl-35850183

ABSTRACT

Cancer treatments are always associated with various challenges, and scientists are constantly trying to find new therapies and methods. Erlotinib (ELT) is a well-known medicine against non-small cell lung cancer (NSCLC). However, treatments by ELT disrupt therapy due to drug resistance and pose severe challenges to patients. To achieve high-performance treatment, we gained nanostructured lipid carriers (NLCs) to evaluate synergistic anticancer effects of co-delivery of ELT and resveratrol (RES), a natural herbal derived phenol against NSCLC. NLCs are prepared via the hot homogenization method and characterized. In vitro cytotoxicity of formulations were evaluated on adenocarcinoma human alveolar basal epithelial (A549) cells. Prepared NLCs showed a narrow particle size (97.52 ± 17.14 nm), negative zeta potential (-7.67 ± 4.55 mV), and high encapsulation efficiency (EE%) was measured for the prepared co-delivery system (EE% 89.5 ± 5.16 % for ELT and 90.1 ± 6.61 % for RES). In vitro outcomes from cell viability study (12.63 % after 48 h of treatment), apoptosis assay (85.50%.), cell cycle (40.00% arrest in G2-M), and western blotting investigations (decreasing of protein expression levels of survivin, Bcl-2, P-Caspase 3P-caspase 9, and P-ERK 1/2, and additionally, increasing protein levels of BAX, P53, C-Caspase 3 and 9), DAPI staining, and colony formation assays showed the augment cytotoxic performances for co-delivery of ELT and RES loaded NLCs. Our study introduced the co-delivery of ELT and RES by NLCs as a novel strategy to elevate the efficacy of chemotherapeutics for NSCLC.


Subject(s)
Carcinoma, Non-Small-Cell Lung , Lung Neoplasms , Nanostructures , Apoptosis , Carcinoma, Non-Small-Cell Lung/drug therapy , Cell Proliferation , Drug Carriers/therapeutic use , Erlotinib Hydrochloride/pharmacology , Humans , Lipids , Lung Neoplasms/drug therapy , Particle Size , Reactive Oxygen Species , Resveratrol
2.
Life Sci ; 283: 119759, 2021 Oct 15.
Article in English | MEDLINE | ID: mdl-34171381

ABSTRACT

AIMS: Skin cancer is the most widespread cancer worldwide, mainly caused by exposure to ultraviolet radiation (UV) in sunlight. Utilizing topical preventive agents in routinely daily used cosmetics may prevent UV-related skin damages and skin cancers. γ-Oryzanol (GO) is a natural component derived from rice bran oil, with potential antioxidant and skin anti-aging properties. MAIN METHODS: We biologically thorough studied the antioxidant and anticancer effects of GO in vitro to found the effective signaling pathways, then evaluated the sun protection factor of prepared formulation, and finally investigated the long-term preventive effects of GO-loaded nanoethosomes (GO-NEs) against UVB-induced skin cancer in mice. KEY FINDINGS: GO-NEs could effectively prevent UVB-induced skin cancer. SIGNIFICANCE: Our results suggest that GO-NEs could be utilized as an innovative ingredient in cosmetics.


Subject(s)
Nanostructures , Phenylpropionates , Skin Neoplasms/prevention & control , Sunscreening Agents , Ultraviolet Rays/adverse effects , Animals , Cell Line, Tumor , Male , Mice , Mice, Inbred BALB C , Nanostructures/chemistry , Nanostructures/therapeutic use , Phenylpropionates/chemistry , Phenylpropionates/pharmacology , Skin Neoplasms/etiology , Skin Neoplasms/metabolism , Skin Neoplasms/pathology , Sunscreening Agents/chemistry , Sunscreening Agents/pharmacology
3.
Drug Discov Today ; 25(8): 1416-1430, 2020 08.
Article in English | MEDLINE | ID: mdl-32622880

ABSTRACT

Effective cancer treatment remains a significant challenge in human healthcare. Although many different types of cancer therapy have been tested, scientists have now concluded that combinations of drugs, or drugs plus gene therapy, can target multiple pathways to fight cancer. Nanovehicles can increase drug uptake inside tumor cells, improve biodistribution and accumulation at tumor sites. The ability to deliver two or more anticancer drugs, genes, among others, at the same time and place will increase therapeutic effects while decreasing side effects and reducing the risk of multidrug resistance. This review discusses the advantages of nano-based co-delivery methods in cancer therapy, summarizes the common types of nanovehicles and their preparation methods, and covers some recent co-delivery studies in detail.


Subject(s)
Antineoplastic Agents/administration & dosage , Drug Delivery Systems , Nanoparticles/administration & dosage , Neoplasms/drug therapy , Animals , Humans
SELECTION OF CITATIONS
SEARCH DETAIL
...